Reuters logo
BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials
June 12, 2017 / 12:30 PM / 6 months ago

BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials

June 12 (Reuters) - Foamix Pharmaceuticals Ltd

* Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%

* Foamix Pharmaceuticals Ltd - “we expect topline data in mid-2018” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below